[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 33 of about 33
1. Miranda Soares PB, Quirino Filho S, Pereira DE Souza W, Ferreti Bonan PR, Martelli-Júnior H: Neuroblastoma in an adult: case report. Rev Med Chil; 2010 Sep;138(9):1131-4
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neuroblastoma in an adult: case report.
  • Neuroblastoma is the most common extracranial solid malignancy in children but rarely described in adults, being 10% of all cases diagnosed after the first decade of life.
  • Immunohistochemical analysis (negative for CD99, CD20, CD3 and desmin; and positive chromogranin, synaptophysin and NB84) confi rmed the diagnosis of neuroblastoma.
  • The patient was submitted to 12 cycles of chemotherapy receiving VAC (vincristine/doxorubicin/cyclophosphamide) interspersed with ICE (ifosfamide/mesna/etoposide) and doxorubicin was replaced by actinomycin in the 7th cycle.
  • She had good tolerance to this therapy, and has been clinically stable.
  • [MeSH-major] Brain Neoplasms / secondary. Neuroblastoma / pathology. Spinal Cord Compression / etiology. Spinal Cord Neoplasms / secondary
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biopsy. Bone Neoplasms / secondary. Carboplatin / administration & dosage. Cyclophosphamide / administration & dosage. Doxorubicin / administration & dosage. Etoposide / administration & dosage. Female. Humans. Ifosfamide / administration & dosage. Mesna / administration & dosage. Thoracic Vertebrae. Vincristine / administration & dosage. Young Adult

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Brain Tumors.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21249281.001).
  • [ISSN] 0034-9887
  • [Journal-full-title] Revista médica de Chile
  • [ISO-abbreviation] Rev Med Chil
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Chile
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide; BG3F62OND5 / Carboplatin; NR7O1405Q9 / Mesna; UM20QQM95Y / Ifosfamide; CAV protocol; ICE protocol 5
  •  go-up   go-down


2. Sasaki T, Okuda K, Zheng W, Butrynski J, Capelletti M, Wang L, Gray NS, Wilner K, Christensen JG, Demetri G, Shapiro GI, Rodig SJ, Eck MJ, Jänne PA: The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers. Cancer Res; 2010 Dec 15;70(24):10038-43
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The neuroblastoma-associated F1174L ALK mutation causes resistance to an ALK kinase inhibitor in ALK-translocated cancers.
  • The ALK kinase inhibitor crizotinib (PF-02341066) is clinically effective in patients with ALK-translocated cancers, but its efficacy will ultimately be limited by acquired drug resistance.
  • Here we report the identification of a secondary mutation in ALK, F1174L, as one cause of crizotinib resistance in a patient with an inflammatory myofibroblastic tumor (IMT) harboring a RANBP2-ALK translocation who progressed while on crizotinib therapy.
  • Our findings highlight the importance of studying drug resistance mechanisms in order to develop effective clinical treatments for patients with ALK-translocated cancers.

  • Genetic Alliance. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] ©2010 AACR.
  • [Cites] Am J Pathol. 2000 Aug;157(2):377-84 [10934142.001]
  • [Cites] Cancer Cell. 2002 Aug;2(2):117-25 [12204532.001]
  • [Cites] Science. 1994 Mar 4;263(5151):1281-4 [8122112.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 Jan 2;104(1):270-5 [17185414.001]
  • [Cites] Blood. 2007 Jun 15;109(12):5143-50 [17317857.001]
  • [Cites] Nature. 2007 Aug 2;448(7153):561-6 [17625570.001]
  • [Cites] Mol Cancer Ther. 2007 Dec;6(12 Pt 1):3314-22 [18089725.001]
  • [Cites] Clin Cancer Res. 2008 Jul 1;14(13):4275-83 [18594010.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):971-4 [18923524.001]
  • [Cites] Nature. 2008 Oct 16;455(7215):975-8 [18923525.001]
  • [Cites] Proc Natl Acad Sci U S A. 2008 Dec 16;105(50):19893-7 [19064915.001]
  • [Cites] Biochemistry. 2009 Jun 16;48(23):5339-49 [19459657.001]
  • [Cites] Nature. 2009 Dec 24;462(7276):1070-4 [20033049.001]
  • [Cites] Clin Cancer Res. 2010 Mar 1;16(5):1561-71 [20179225.001]
  • [Cites] Biochemistry. 2010 Aug 17;49(32):6813-25 [20695522.001]
  • [Cites] Biochem J. 2010 Sep 15;430(3):425-37 [20632993.001]
  • [Cites] N Engl J Med. 2010 Oct 28;363(18):1727-33 [20979472.001]
  • (PMID = 21030459.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA136851-03; United States / NCI NIH HHS / CA / P50CA090578; United States / NCI NIH HHS / CA / R01CA136851; United States / NCI NIH HHS / CA / CA136851-03; United States / NCI NIH HHS / CA / R01CA135257; United States / NCI NIH HHS / CA / P50 CA090578; United States / NCI NIH HHS / CA / R01 CA135257-04; United States / NCI NIH HHS / CA / R01 CA135257; United States / NCI NIH HHS / CA / R01 CA136851
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / EML4-ALK fusion protein, human; 0 / Oncogene Proteins, Fusion; 0 / Protein Kinase Inhibitors; 0 / Pyrazoles; 0 / Pyridines; 53AH36668S / crizotinib; EC 2.7.10.1 / Protein-Tyrosine Kinases; EC 2.7.10.1 / Receptor Protein-Tyrosine Kinases; EC 2.7.10.1 / anaplastic lymphoma kinase
  • [Other-IDs] NLM/ NIHMS265602; NLM/ PMC3045808
  •  go-up   go-down


3. Kayton ML, He M, Zakowski MF, Moreira AL, Lau C, Chou AJ, Merchant M, Merola PR, Wexler LH, La Quaglia MP, Travis WD, Ladanyi M: Primary lung adenocarcinomas in children and adolescents treated for pediatric malignancies. J Thorac Oncol; 2010 Nov;5(11):1764-71
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • There have been anecdotal reports of lesions that are histologically indistinguishable from adult-type pulmonary adenocarcinoma in young patients after treatment for nonpulmonary cancers.
  • Median age at nonpulmonary cancer diagnosis was 14 years (range, 3-23 years).
  • Retrospective review showed that in at least three patients, the nodules were radiographically present before chemotherapy.
  • CONCLUSIONS: Pulmonary lesions found in young patients with pediatric cancers can be histologically indistinguishable from lung adenocarcinoma seen in adults, may display typical adenocarcinoma-associated mutations of EGFR and KRAS, and may precede the administration of cytotoxic chemotherapy.

  • MedlinePlus Health Information. consumer health - Bone Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • MedlinePlus Health Information. consumer health - Wilms Tumor.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Pediatr Blood Cancer. 2005 Oct 15;45(5):683-6 [15714450.001]
  • [Cites] J Mol Diagn. 2005 Aug;7(3):396-403 [16049312.001]
  • [Cites] J Clin Oncol. 2006 Apr 1;24(10):1529-34 [16575003.001]
  • [Cites] Thorac Surg Clin. 2006 May;16(2):167-83, vi [16805206.001]
  • [Cites] N Engl J Med. 2006 Oct 12;355(15):1572-82 [17035650.001]
  • [Cites] Ann Thorac Surg. 2007 Feb;83(2):687-9 [17258019.001]
  • [Cites] J Thorac Oncol. 2006 Nov;1(9 Suppl):S27-31 [17409998.001]
  • [Cites] J Thorac Oncol. 2006 Nov;1(9 Suppl):S8-12 [17410000.001]
  • [Cites] J Pediatr Surg. 2007 May;42(5):E1-4 [17502169.001]
  • [Cites] Am J Surg Pathol. 2007 Jun;31(6):961-9 [17527088.001]
  • [Cites] Lung Cancer. 2008 Aug;61(2):266-9 [18394748.001]
  • [Cites] Clin Cancer Res. 2008 Sep 15;14(18):5731-4 [18794081.001]
  • [Cites] Oncogene. 2009 Aug 6;28(31):2773-83 [19525976.001]
  • [Cites] Lancet Oncol. 2010 Apr;11(4):321-30 [20304703.001]
  • [Cites] Can Assoc Radiol J. 1999 Oct;50(5):343-5 [10555511.001]
  • [Cites] Ann Thorac Surg. 2001 Mar;71(3):956-60; discussion 961 [11269480.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1525-30 [11745231.001]
  • [Cites] Med Pediatr Oncol. 2002 Feb;38(2):125-7 [11813181.001]
  • [Cites] Ann Thorac Surg. 2002 Apr;73(4):1055-8; discussion 1058-9 [11996240.001]
  • [Cites] Ann Thorac Surg. 2002 Apr;73(4):1071-5 [11996243.001]
  • [Cites] Ann Thorac Surg. 2002 May;73(5):1594-8 [12022556.001]
  • [Cites] Pediatr Hematol Oncol. 2002 Sep;19(6):421-8 [12186365.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Apr;125(4):924-8 [12698157.001]
  • [Cites] Am J Surg Pathol. 2003 Aug;27(8):1139-46 [12883247.001]
  • [Cites] J Thorac Cardiovasc Surg. 2003 Sep;126(3):902-3 [14502190.001]
  • [Cites] Lung Cancer. 2004 Apr;44(1):61-8 [15013584.001]
  • [Cites] J Pediatr Hematol Oncol. 2004 Jul;26(7):457-61 [15218424.001]
  • [Cites] Ann Thorac Surg. 1983 Jul;36(1):108-19 [6344822.001]
  • [Cites] Cancer Res. 1988 Oct 15;48(20):5738-41 [3048648.001]
  • [Cites] Mod Pathol. 1988 Sep;1(5):372-7 [2853363.001]
  • [Cites] Med Pediatr Oncol. 1989;17(6):510-3 [2586365.001]
  • [Cites] Tumori. 1989 Oct 31;75(5):449-51 [2557691.001]
  • [Cites] Am J Clin Pathol. 1991 Jun;95(6):889-92 [1645926.001]
  • [Cites] Clin Pediatr (Phila). 1992 Apr;31(4):253-4 [1314155.001]
  • [Cites] Thorac Cardiovasc Surg. 1994 Feb;42(1):61-3 [8184398.001]
  • [Cites] Cancer. 1995 Jun 15;75(12):2844-52 [7773933.001]
  • [Cites] Ann Thorac Surg. 1995 Sep;60(3):615-22; discussion 622-3 [7677489.001]
  • [Cites] Ann Thorac Surg. 1995 Oct;60(4):1126-8 [7574970.001]
  • [Cites] J Clin Oncol. 1996 Oct;14(10):2818-25 [8874344.001]
  • [Cites] Chest. 1997 Aug;112(2):548-51 [9266899.001]
  • [Cites] Pediatr Pulmonol. 1998 Jan;25(1):62-6 [9475333.001]
  • [Cites] J Pediatr Surg. 1998 May;33(5):730-2 [9607481.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Oct;118(4):702-9 [10504637.001]
  • [Cites] Jpn J Thorac Cardiovasc Surg. 2005 Jan;53(1):29-35 [15724499.001]
  • [Cites] J Natl Cancer Inst. 2005 Mar 2;97(5):339-46 [15741570.001]
  • [Cites] Histopathology. 2006 Jan;48(2):204-6 [16405673.001]
  • (PMID = 20975376.001).
  • [ISSN] 1556-1380
  • [Journal-full-title] Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
  • [ISO-abbreviation] J Thorac Oncol
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / P01 CA129243; United States / NCI NIH HHS / CA / P01-CA129243
  • [Publication-type] Case Reports; Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / KRAS protein, human; 0 / Proto-Oncogene Proteins; EC 2.7.10.1 / EGFR protein, human; EC 2.7.10.1 / Receptor, Epidermal Growth Factor; EC 3.6.5.2 / ras Proteins
  • [Other-IDs] NLM/ NIHMS641346; NLM/ PMC4243865
  •  go-up   go-down


Advertisement
4. Dabrowski A, Filip A, Zgodziński W, Dabrowska M, Polańska D, Wójcik M, Zinkiewicz K, Wallner G: Assessment of prognostic significance of cytoplasmic survivin expression in advanced oesophageal cancer. Folia Histochem Cytobiol; 2004;42(3):169-72
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Expression of survivin was found in colorectal cancer, neuroblastoma, bladder cancer, non-small cell lung cancer, and breast cancer.
  • There is some recent data indicating the correlation of poor prognosis and worse response to chemotherapy in patients with oesophageal squamous cell carcinoma (OSCC) expressing survivin.
  • The aim of the present study was to assess survivin expression in cancerous tissue of patients with advanced OSCC and to test the potential correlation between survivin expression and clinicopathological data.
  • Forty two patients (mean age 58.36+/-8.97 yrs), who were oesophagectomised due to squamous cell carcinoma of the thoracic oesophagus between 1998 and 2000, were retrospectively analysed.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15493578.001).
  • [ISSN] 0239-8508
  • [Journal-full-title] Folia histochemica et cytobiologica
  • [ISO-abbreviation] Folia Histochem. Cytobiol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Chemical-registry-number] 0 / BIRC5 protein, human; 0 / Inhibitor of Apoptosis Proteins; 0 / Microtubule-Associated Proteins; 0 / Neoplasm Proteins
  •  go-up   go-down


5. Sucker C, Dölken G, Lorenz G, Fiedler W, Stockschläder M: [Thoracic neuroblastoma in a young adult]. Dtsch Med Wochenschr; 2004 Feb 6;129(6):249-52
Hazardous Substances Data Bank. ALL-TRANS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Thoracic neuroblastoma in a young adult].
  • EXAMINATIONS: Diagnostic imaging showed an extensive thoracic tumor and enlarged mediastinal and cervical lymph nodes.
  • The diagnosis of neuroblastoma was established by biopsy.
  • TREATMENT AND CLINICAL COURSE: The patient was treated with a polychemotherapy protocol according to the pediatric neuroblastoma study NB97.
  • Subsequently, the patient underwent partial tumor resection, received two further chemotherapy courses and irradiation of the remaining tumor.
  • Because of residual vital tumor cells, a second surgical tumour reduction followed by high-dose chemotherapy with autologous stem-cell support was performed.
  • Six months after the end of therapy, the patient is in a good condition despite of the presence of residual tumor.
  • CONCLUSION: Neuroblastoma is a very rare tumor in adult patients.
  • Therapy is multimodal and should follow pediatric guidelines for neuroblastoma treatment.
  • [MeSH-major] Neuroblastoma / diagnosis. Neuroblastoma / therapy. Thoracic Neoplasms / diagnosis. Thoracic Neoplasms / therapy
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Chemotherapy, Adjuvant. Combined Modality Therapy. Diagnosis, Differential. Humans. Magnetic Resonance Imaging. Male. Radiotherapy, Adjuvant. Reoperation. Stem Cell Transplantation. Transplantation, Autologous. Tretinoin / administration & dosage

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14750051.001).
  • [ISSN] 0012-0472
  • [Journal-full-title] Deutsche medizinische Wochenschrift (1946)
  • [ISO-abbreviation] Dtsch. Med. Wochenschr.
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 5688UTC01R / Tretinoin
  •  go-up   go-down


6. Remmers D, Bökkerink JP, Katsaros C: Microdontia after chemotherapy in a child treated for neuroblastoma. Orthod Craniofac Res; 2006 Nov;9(4):206-10
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Microdontia after chemotherapy in a child treated for neuroblastoma.
  • OBJECTIVE: Chemotherapy used on paediatric oncology patients often causes disturbances in dental development.
  • Aim of this case report is to present the late effects of chemotherapy on dental development in a patient treated for neuroblastoma at early age.
  • RESULTS: This paper presents a female patient treated at early age with surgery and chemotherapy for a neuroblastoma (stage IVS) in the right thorax and massive liver metastases.
  • CONCLUSIONS: Chemotherapy on children treated for neuroblastoma can adversely influence tooth development.
  • [MeSH-major] Antineoplastic Agents / adverse effects. Liver Neoplasms / drug therapy. Neuroblastoma / drug therapy. Thoracic Neoplasms / drug therapy. Tooth Abnormalities / chemically induced
  • [MeSH-minor] Child. Female. Humans. Odontogenesis / drug effects. Tooth Crown / abnormalities. Tooth Crown / drug effects. Tooth Root / abnormalities. Tooth Root / drug effects

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17101028.001).
  • [ISSN] 1601-6335
  • [Journal-full-title] Orthodontics & craniofacial research
  • [ISO-abbreviation] Orthod Craniofac Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


7. Walter KN, Kratz C, Uhl M, Niemeyer C: Chemotherapy as a therapeutic option for congenital neuroblastoma complicated by paraplegia. Klin Padiatr; 2008 May-Jun;220(3):175-7
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy as a therapeutic option for congenital neuroblastoma complicated by paraplegia.
  • BACKGROUND: Spinal compression can be a complication of neuroblastoma (NBL).
  • Delayed or insufficient treatment of this condition may lead to permanent neurological sequelae.
  • Therefore, appropriate treatment should be introduced promptly.
  • Therapeutic options include neurosurgery, chemotherapy, and radiation therapy.
  • Tumor size diminished quickly and neurological symptoms partly recovered after the patient received chemotherapy consisting of vincristine, doxorubicine, and cyclophosphamide.
  • CONCLUSION: Rapid initiation of chemotherapy was safe and effective in a neonate with NBL complicated by spinal cord compression.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Lumbar Vertebrae. Neuroblastoma / congenital. Neuroblastoma / drug therapy. Paraplegia / congenital. Spinal Cord Compression / congenital. Spinal Neoplasms / congenital. Spinal Neoplasms / drug therapy. Thoracic Vertebrae
  • [MeSH-minor] Child, Preschool. Cyclophosphamide / administration & dosage. Cyclophosphamide / adverse effects. Doxorubicin / administration & dosage. Doxorubicin / adverse effects. Follow-Up Studies. Humans. Infant. Infant, Newborn. Magnetic Resonance Imaging. Male. Neurologic Examination / drug effects. Vincristine / administration & dosage. Vincristine / adverse effects

  • Genetic Alliance. consumer health - Neuroblastoma.
  • Genetic Alliance. consumer health - Paraplegia.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18478490.001).
  • [ISSN] 0300-8630
  • [Journal-full-title] Klinische Pädiatrie
  • [ISO-abbreviation] Klin Padiatr
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 5J49Q6B70F / Vincristine; 80168379AG / Doxorubicin; 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


8. Shimizu M, Shimizu T, Adachi T, Nishiuchi M, Kanzaki M, Onuki T: Long-term survival in adult mediastinal neuroblastoma. Jpn J Thorac Cardiovasc Surg; 2003 Jul;51(7):326-9
Hazardous Substances Data Bank. CYCLOPHOSPHAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Long-term survival in adult mediastinal neuroblastoma.
  • Neuroblastoma rarely occurs in adults, in whom prognosis is poor.
  • Here we report on the effective use of multimodal therapy to achieve long-term survival in adult mediastinal neuroblastoma.
  • Chest X-rays and chest CT scans revealed a posterior mediastinal mass beside the thoracic vertebrae.
  • Diagnosis was confirmed after surgical resection, which was followed by outpatient adjuvant therapy through radiation and chemotherapy.
  • [MeSH-major] Mediastinal Neoplasms / mortality. Neuroblastoma / mortality
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols. Combined Modality Therapy. Cyclophosphamide / administration & dosage. Humans. Male. Radiotherapy, Adjuvant. Survival Analysis. Thoracotomy. Time Factors. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12892467.001).
  • [ISSN] 1344-4964
  • [Journal-full-title] The Japanese journal of thoracic and cardiovascular surgery : official publication of the Japanese Association for Thoracic Surgery = Nihon Kyōbu Geka Gakkai zasshi
  • [ISO-abbreviation] Jpn. J. Thorac. Cardiovasc. Surg.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 8N3DW7272P / Cyclophosphamide
  •  go-up   go-down


9. DeCou JM, Schlatter MG, Mitchell DS, Abrams RS: Primary thoracoscopic gross total resection of neuroblastoma. J Laparoendosc Adv Surg Tech A; 2005 Oct;15(5):470-3
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary thoracoscopic gross total resection of neuroblastoma.
  • BACKGROUND: Thoracic neuroblastomas are generally less aggressive and have a better prognosis than those arising below the diaphragm.
  • PATIENTS AND METHODS: We reviewed the records of patients who underwent primary thoracoscopic resection of neuroblastoma (NB) between 1998 and 2002.
  • Data included demographics, symptoms, size, location, operative time, complications, hospital stay, histology, biologic markers, adjuvant therapy, and outcome.
  • Operative time ranged from 64 to 175 minutes.
  • Chemotherapy or radiation therapy was not indicated for any patient.
  • [MeSH-major] Neuroblastoma / surgery. Thoracic Neoplasms / surgery. Thoracoscopy

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16185118.001).
  • [ISSN] 1092-6429
  • [Journal-full-title] Journal of laparoendoscopic & advanced surgical techniques. Part A
  • [ISO-abbreviation] J Laparoendosc Adv Surg Tech A
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Michalowski MB, Rubie H, Michon J, Montamat S, Bergeron C, Coze C, Perel Y, Valteau-Couanet D, Guitard J, Guys JM, Piolat C, Munzer C, Plantaz D, Groupe Neuroblastome de la Société Française d'Oncologie Pédiatrique: [Neonatal localized neuroblastoma: 52 cases treated from 1990 to 1999]. Arch Pediatr; 2004 Jul;11(7):782-8
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Neonatal localized neuroblastoma: 52 cases treated from 1990 to 1999].
  • Neuroblastoma is the most frequent tumor observed in the newborn.
  • The aim of this study was to review clinical features, treatment and outcome of newborns diagnosed with a localized neuroblastoma.
  • RESULTS: The median age at diagnosis was 12 days (range 0-28) with antenatal detection in 14 patients (27%).
  • Tumor location was abdominal in 40 patients (adrenal in 20 of the 40), thoracic in eight, pelvic in three, and cervical in one.
  • One child died from hemorrhage after fine needle biopsy during diagnostic procedure.
  • Tumor was deemed as unresectable in 14 patients, and primary chemotherapy was given followed by surgical excision in 12.
  • One of them died a few days after the beginning of chemotherapy.
  • Indeed, chemotherapy based on weight and managed by expert teams should allow to perform surgical excision in safer conditions for unresectable tumors.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neuroblastoma / drug therapy. Neuroblastoma / surgery
  • [MeSH-minor] Female. Humans. Infant, Newborn. Infant, Newborn, Diseases. Male. Prognosis. Retrospective Studies. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15234372.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


11. Lobato R, Queizán A, Martínez L, Díaz M, Gámez M, Tovar JA: [Impact of complete resection on survival of patients with large neuroblastoma]. Cir Pediatr; 2000 Jan;13(1):14-5
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Impact of complete resection on survival of patients with large neuroblastoma].
  • The aim of our study is to assess the role of complete resection after chemotherapy in stage 3 and 4 (INSS) neuroblastoma.
  • 47 were abdominal, 13 thoracic, 2 pelvic and 1 cervical.
  • CONCLUSIONS: Complete resection in stage 3 neuroblastoma after chemotherapy improves survival, and radical surgery seems justified even if neighboring structures have to be removed.
  • Radical surgery does not seem to be useful in stage 4 neuroblastoma.
  • [MeSH-major] Ganglioneuroma / mortality. Ganglioneuroma / surgery. Neuroblastoma / mortality. Neuroblastoma / surgery
  • [MeSH-minor] Child, Preschool. Humans. Infant. Neoplasm Staging. Survival Rate

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12602016.001).
  • [ISSN] 0214-1221
  • [Journal-full-title] Cirugía pediátrica : organo oficial de la Sociedad Española de Cirugía Pediátrica
  • [ISO-abbreviation] Cir Pediatr
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


12. Luehr M, Siepe M, Beyersdorf F, Schlensak C: Extra-anatomic bypass for recurrent abdominal aortic and renal in-stent stenoses following radiotherapy for neuroblastoma. Interact Cardiovasc Thorac Surg; 2009 Apr;8(4):488-90
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Extra-anatomic bypass for recurrent abdominal aortic and renal in-stent stenoses following radiotherapy for neuroblastoma.
  • We describe the case of an 11-year-old girl with an abdominal neuroblastoma which was operated and intraoperatively irradiated nine years ago.
  • After six years, she developed stenoses of the infrarenal abdominal aorta and both renal arteries.
  • Initial treatment of the stenosed vessels comprised endovascular balloon dilatations and repeated stent-graft implantations, including drug eluting stents.
  • However, severe in-stent stenoses occurred during follow-up and the girl developed acute renal failure.
  • Open surgery was performed with two extra-anatomic bypasses, a thoracic-to-abdominal aortic bypass and a left iliac-to-renal bypass, on an urgent basis.
  • We conclude that endovascular stent-graft placement in children can only be a palliative treatment due to outgrowing of the stent-graft and the potential risk of re-stenosis, especially after a history of irradiation.
  • Vascular surgery with placement of extra-anatomic bypasses will provide a definite treatment.
  • [MeSH-major] Abdominal Neoplasms / radiotherapy. Angioplasty, Balloon / instrumentation. Aorta, Abdominal / surgery. Aortic Diseases / therapy. Blood Vessel Prosthesis Implantation. Drug-Eluting Stents. Neuroblastoma / radiotherapy. Radiation Injuries / therapy. Renal Artery Obstruction / therapy
  • [MeSH-minor] Acute Kidney Injury / etiology. Acute Kidney Injury / surgery. Angiography, Digital Subtraction. Aorta, Thoracic / surgery. Aortography / methods. Blood Vessel Prosthesis. Child. Constriction, Pathologic. Female. Humans. Iliac Artery / surgery. Palliative Care. Radiotherapy / adverse effects. Recurrence. Tomography, X-Ray Computed. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19126553.001).
  • [ISSN] 1569-9285
  • [Journal-full-title] Interactive cardiovascular and thoracic surgery
  • [ISO-abbreviation] Interact Cardiovasc Thorac Surg
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  •  go-up   go-down


13. Paulino AC, Fowler BZ: Risk factors for scoliosis in children with neuroblastoma. Int J Radiat Oncol Biol Phys; 2005 Mar 1;61(3):865-9
MedlinePlus Health Information. consumer health - Scoliosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Risk factors for scoliosis in children with neuroblastoma.
  • PURPOSE: To determine the risk factors for scoliosis in children treated for neuroblastoma.
  • METHODS AND MATERIALS: From 1957 to 1997, 58 children with neuroblastoma were treated at one institution and have survived a minimum of 5 years.
  • There were 35 boys and 23 girls with a median age of 6 months (range, 2 weeks to 15 years) at initial diagnosis.
  • Primary site was located in the adrenal gland in 25 (43.1%), abdominal/nonadrenal in 16 (27.6%), thoracic in 12 (20.7%), cervical in 3 (5.3%), and pelvic region in 2 (3.5%).
  • The International Neuroblastoma Staging System (INSS) stage was Stage 1 in 10 (17.2%), Stage 2A in 7 (12.1%), Stage 2B in 5 (8.6%), Stage 3 in 22 (37.9%), Stage 4 in 4 (6.9%), and Stage 4S in 10 (17.2%).
  • Thirty-three (56.9%) received chemotherapy whereas 5 (8.6%) had a laminectomy as part of the surgical procedure.
  • Twelve (21%) developed scoliosis at a median time of 51 months (range, 8-137 months).
  • Four had scoliosis ranging from 30 degrees to 66 degrees ; 3 of these patients required surgical intervention, whereas 1 had an underlying Duchenne muscular dystrophy which manifested itself 8 years after diagnosis of neuroblastoma.
  • Median time to scoliosis was 23 months (range, 8-54 months) in children who had a laminectomy.
  • Gender, age at diagnosis, INSS stage, primary site, and use of chemotherapy were not found to be significant.
  • CONCLUSIONS: Treatment-related factors, namely laminectomy and radiotherapy, were found to increase the risk of scoliosis in patients with neuroblastoma.
  • [MeSH-major] Neuroblastoma / radiotherapy. Scoliosis / etiology
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Follow-Up Studies. Humans. Infant. Infant, Newborn. Laminectomy / adverse effects. Male. Multivariate Analysis. Neoplasm Staging. Radiotherapy Dosage. Risk Factors

  • Genetic Alliance. consumer health - Neuroblastoma.
  • Genetic Alliance. consumer health - Scoliosis.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15708267.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Gatcombe HG, Marcus RB Jr, Katzenstein HM, Tighiouart M, Esiashvili N: Excellent local control from radiation therapy for high-risk neuroblastoma. Int J Radiat Oncol Biol Phys; 2009 Aug 1;74(5):1549-54
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Excellent local control from radiation therapy for high-risk neuroblastoma.
  • PURPOSE: Local recurrence has been demonstrated in previous studies to be one of the obstacles to cure in neuroblastoma.
  • Radiation therapy indications, optimal dose, and technique are still evolving.
  • Here we report our experience of high-risk neuroblastoma patients who received local radiation therapy as part of their cancer management.
  • METHODS AND MATERIALS: We conducted a retrospective study of 34 high-risk neuroblastoma patients who received radiation therapy to local sites of disease from March 2001 until February 2007 at our institution as part of their multimodality therapy.
  • Both of these patients had persistent gross disease after induction chemotherapy and surgery.
  • CONCLUSION: Patients with high-risk neuroblastoma in our series achieved excellent local control.
  • Doses of 21-24 Gy to the primary tumor site appear to be adequate for local control for patients in the setting of minimal residual disease after induction chemotherapy and surgery.
  • [MeSH-major] Neuroblastoma / radiotherapy
  • [MeSH-minor] Abdominal Neoplasms / drug therapy. Abdominal Neoplasms / mortality. Abdominal Neoplasms / radiotherapy. Abdominal Neoplasms / surgery. Adolescent. Antineoplastic Agents / therapeutic use. Child. Child, Preschool. Combined Modality Therapy / methods. Disease-Free Survival. Female. Gene Amplification. Genes, myc / genetics. Humans. Infant. Male. Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / mortality. Pelvic Neoplasms / radiotherapy. Pelvic Neoplasms / surgery. Radiotherapy Dosage. Remission Induction. Retrospective Studies. Risk. Thoracic Neoplasms / drug therapy. Thoracic Neoplasms / mortality. Thoracic Neoplasms / radiotherapy. Thoracic Neoplasms / surgery. Young Adult

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19211198.001).
  • [ISSN] 1879-355X
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  •  go-up   go-down


15. Sauvat F, Brisse H, Magdeleinat P, Lopez M, Philippe-Chomette P, Orbach D, Aerts I, Brugieres L, Revillon Y, Sarnacki S: The transmanubrial approach: a new operative approach to cervicothoracic neuroblastoma in children. Surgery; 2006 Jan;139(1):109-14
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The transmanubrial approach: a new operative approach to cervicothoracic neuroblastoma in children.
  • BACKGROUND: Cervicothoracic neuroblastoma originates from the cervical sympathetic nerves and ganglia and thus presents a problem when dissecting the vascular and nervous elements of the subclavian region.
  • We report our experience in children with cervicothoracic neuroblastoma by using a technique usually performed for apical lung cancer.
  • METHODS: Four patients with localized cervicothoracic neuroblastoma with no N-myc amplification were resected after chemotherapy by this approach.
  • This transmanubrial approach, performed through a manubrial L-shaped transection and first costal cartilage resection, affords excellent access to the subclavian region with safe control of the vessels and nerves and exposure of the first 4 thoracic intervertebral foramina.
  • CONCLUSIONS: The transmanubrial approach is an osteomuscular-sparing technique that seems particularly suitable for the treatment of these tumors, which require a resection that is as complete as possible to avoid postoperative chemotherapy and tumor relapse.
  • [MeSH-major] Nervous System Neoplasms / surgery. Neuroblastoma / surgery. Neurosurgical Procedures. Sympathetic Nervous System
  • [MeSH-minor] Cervical Vertebrae. Child. Child, Preschool. Female. Humans. Infant. Magnetic Resonance Imaging. Radiography, Thoracic. Thoracic Vertebrae

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16364724.001).
  • [ISSN] 0039-6060
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Mitchell WG, Davalos-Gonzalez Y, Brumm VL, Aller SK, Burger E, Turkel SB, Borchert MS, Hollar S, Padilla S: Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae. Pediatrics; 2002 Jan;109(1):86-98
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae.
  • OBJECTIVE: Opsoclonus-ataxia, also called "dancing eye syndrome," is a serious neurologic condition that is often a paraneoplastic manifestation of occult neuroblastoma in early childhood.
  • Despite resection of tumor and immunosuppressive therapy, outcome generally includes significant developmental and behavioral sequelae.
  • There is controversy about how treatment alters outcome.
  • The goals of this study were to understand the ongoing neurologic and developmental deficits of children who are treated for opsoclonus-ataxia with associated neuroblastoma; to relate treatment history to outcome; and to quantify objectively the acute changes in motor function, speech, mood, and behavior related to intravenous immunoglobulin (IVIg) treatment.
  • METHODS: Patients were children with opsoclonus-ataxia caused by neuroblastoma, regardless of interval since diagnosis.
  • Additional examinations were performed immediately before and 2 to 3 days after treatment with IVIg in 5 children.
  • All had a stage I or II neuroblastoma resected 3 months to 11 years previously.
  • None received any other treatment for the tumor.
  • Three had received other immunosuppressive treatment, including cyclophosphamide.
  • Immediate versus delayed treatment was not associated with better outcome.
  • CONCLUSIONS: Opsoclonus-ataxia caused by neuroblastoma causes substantial developmental sequelae that are not adequately prevented by current treatment.
  • The increased deficits in older children raise concern that this represents a progressive encephalopathy rather than a time-limited single insult.
  • [MeSH-major] Abdominal Neoplasms / complications. Ataxia / etiology. Neuroblastoma / complications. Paraneoplastic Syndromes, Nervous System / etiology. Thoracic Neoplasms / complications
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Cross-Sectional Studies. Female. Head and Neck Neoplasms / complications. Head and Neck Neoplasms / diagnosis. Head and Neck Neoplasms / drug therapy. Humans. Immunoglobulins, Intravenous / therapeutic use. Infant. Male

  • Genetic Alliance. consumer health - Neuroblastoma.
  • Genetic Alliance. consumer health - Ataxia.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [ErratumIn] Pediatrics 2002 Oct;110(4):853-4
  • (PMID = 11773546.001).
  • [ISSN] 1098-4275
  • [Journal-full-title] Pediatrics
  • [ISO-abbreviation] Pediatrics
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Immunoglobulins, Intravenous
  •  go-up   go-down


17. Tang SQ, Huang DS, Wang JW, Zhang XF, Liu LZ, Yu F, Yang G: [Treatment of high-risk neuroblastoma with intensive chemotherapy, autologous peripheral blood stem cell transplantation, and 13-cis-retinoic acid]. Zhonghua Er Ke Za Zhi; 2004 Jul;42(7):486-9
Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of high-risk neuroblastoma with intensive chemotherapy, autologous peripheral blood stem cell transplantation, and 13-cis-retinoic acid].
  • OBJECTIVE: The prognosis for neuroblastoma in advanced stage is still poor, even under conventional chemotherapy.
  • This study aimed to investigate if very high dose chemotherapy in conjunction with autologous peripheral blood stem cell transplantation and 13-cis-retinoic acid could get excellent results in children with high risk neuroblastoma.
  • METHODS: Six children, aged from 4 to 8 years, with stage IV neuroblastoma were included in the study.
  • Primary sites of the diseases were in the abdominal cavity (n = 5) and thoracic cavity (n = 1).
  • All of the patients received very high dose chemotherapy, surgery, local radiation (20-30 Gy), and autologous peripheral blood stem cell transplantation as well as 13-cis retinoic acid.
  • Induction chemotherapy included vincristine 0.67 mg/(m2 x 24 h, x 3), cyclophosphamide 2.1 g/(m2 x 24 h, x 2) and doxorubicin 25 mg/(m2 x 24 h, x 3) for 4 courses.
  • Drugs were given as 24 hour-continuous intravenous infusion.
  • 13-cis retinoic acid 160 mg/(m2.d) started on +59 days for 6 courses, each course including 14 days therapy and 14 days rest.
  • However, marrow suppression due to very high dose chemotherapy occurred in all of the patients, which lasted for 3-4 weeks for peripheral leukocyte recovery.
  • Fever occurred after they finished 1/3 course of chemotherapy.
  • CONCLUSION: The new strategies focused on very high dose chemotherapy, autologous peripheral blood stem cell transplantation and biological therapy might be a good option for patients with advance neuroblastoma.
  • [MeSH-major] Abdominal Neoplasms / therapy. Isotretinoin / therapeutic use. Neuroblastoma / therapy. Peripheral Blood Stem Cell Transplantation
  • [MeSH-minor] Bone Marrow Cells / metabolism. Child, Preschool. Female. Follow-Up Studies. Humans. Male. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • Genetic Alliance. consumer health - Transplantation.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15324562.001).
  • [ISSN] 0578-1310
  • [Journal-full-title] Zhonghua er ke za zhi = Chinese journal of pediatrics
  • [ISO-abbreviation] Zhonghua Er Ke Za Zhi
  • [Language] chi
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] EH28UP18IF / Isotretinoin
  •  go-up   go-down


18. Cecchetto G, Mosseri V, De Bernardi B, Helardot P, Monclair T, Costa E, Horcher E, Neuenschwander S, Tomà P, Rizzo A, Michon J, Holmes K: Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group. J Clin Oncol; 2005 Nov 20;23(33):8483-9
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical risk factors in primary surgery for localized neuroblastoma: the LNESG1 study of the European International Society of Pediatric Oncology Neuroblastoma Group.
  • PURPOSE: Although tumor resection is the mainstay of treatment for localized neuroblastoma, there are no established guidelines indicating which patients should be operated on immediately and which should undergo surgery after tumor reduction with chemotherapy.
  • PATIENTS AND METHODS: A total of 905 patients with suspected localized neuroblastoma were registered by 10 European countries between January 1995 and October 1999; 811 of 905 patients were eligible for this analysis.
  • Additional studies aiming to better define the surgical approach to localized neuroblastoma are warranted.
  • [MeSH-major] Abdominal Neoplasms / surgery. Head and Neck Neoplasms / surgery. Neuroblastoma / surgery. Risk Management. Thoracic Neoplasms / surgery

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16293878.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


19. Plantaz D, Michon J, Valteau-Couanet D, Coze C, Chastagner P, Bergeron C, Nelken B, Martelli H, Peyroulet MC, Carpentier AF, Armari-Alla C, Pagnier A, Rubie H: [Opsoclonus-myoclonus syndrome associated with non-metastatic neuroblastoma. Long-term survival. Study of the French Society of Pediatric Oncologists]. Arch Pediatr; 2000 Jun;7(6):621-8
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Opsoclonus-myoclonus syndrome associated with non-metastatic neuroblastoma. Long-term survival. Study of the French Society of Pediatric Oncologists].
  • In children, it could be a paraneoplastic syndrome in association with neuroblastoma, usually with a high survival rate, but having a high frequency of neurologic and psychologic sequelae.
  • OBJECTIVES: The aim of this study was to describe oncologic outcome (prospectively) and neurologic outcome (retrospectively) in children with non-metastatic neuroblastoma, and to determine its best treatment.
  • PATIENTS AND METHODS: Data were collected on 21 children diagnosed with localized neuroblastoma and opsoclonus-myoclonus between 1990-1999 from the French Society of Pediatric Oncology institutions.
  • RESULTS: Median age at diagnosis was 18 months.
  • Location of the tumor was abdominal in 14 cases, thoracic in three cases, pelvic in three cases, and cervical in the last case.
  • Only four tumors were initially considered as unresectable tumors and received first-line chemotherapy.
  • Complete macroscopic resection was performed in 20 cases (four after primary chemotherapy).
  • Nine children received chemotherapy.
  • Treatment for opsoclonus-myoclonus varied widely.
  • Only one child received no medical treatment for opsoclonus-myoclonus, because of complete resolution of neurologic symptoms after exclusive surgery.
  • The following agents were used: corticosteroids in 18 cases, intravenously immune globulin in five cases, and antiepileptic drugs in seven cases.
  • Ten patients experienced relapses of opsoclonus-myoclonus symptoms, mainly related to the decrease of steroid therapy (5/10).
  • There is no correlation between neurologic outcome, and either age at diagnosis or duration of neurologic symptoms, or type of treatment of the tumor, particularly chemotherapy.
  • CONCLUSION: Persistent neurologic deficits are characteristic for children with neuroblastoma and opsoclonus-myoclonus.
  • Neurologic outcome seems unrelated to the treatment of neuroblastoma, which should exclusively be conducted according to oncological criteria.
  • The treatment of opsoclonus-myoclonus should be standardized, mainly based on high-dose hydrocortisone, with a very low decreasing dosage, associated to intravenously immune globulin in severe cases.
  • [MeSH-major] Neuroblastoma / complications. Paraneoplastic Syndromes, Nervous System / etiology
  • [MeSH-minor] Adolescent. Adrenal Cortex Hormones / therapeutic use. Adult. Anticonvulsants / therapeutic use. Child. Female. Humans. Immunization, Passive. Male. Prognosis. Prospective Studies. Retrospective Studies. Risk Factors. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Dancing Eyes-Dancing Feet Syndrome.
  • Genetic Alliance. consumer health - Myoclonus.
  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10911528.001).
  • [ISSN] 0929-693X
  • [Journal-full-title] Archives de pédiatrie : organe officiel de la Sociéte française de pédiatrie
  • [ISO-abbreviation] Arch Pediatr
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] FRANCE
  • [Chemical-registry-number] 0 / Adrenal Cortex Hormones; 0 / Anticonvulsants
  •  go-up   go-down


20. Bastian PJ, Fleischhack G, Zimmermann M, Hasan C, Bode U, Müller SC, Schumacher S: The role of complete surgical resection in stage IV neuroblastoma. World J Urol; 2004 Oct;22(4):257-60
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The role of complete surgical resection in stage IV neuroblastoma.
  • The purpose of this study was to examine the outcome of attempted radical surgical resection in patients with stage IV neuroblastoma.
  • Between 1989 and 2003, 20 (median age 2.4 years, range 0.5-8.7 years) children with stage IV neuroblastoma were treated at the Department of Pediatrics.
  • Mean age at diagnosis was 57 months (21-104 months).
  • Mean age at the time of surgery was 54 months (8-390 months).
  • Primary localization of the tumor was retroperitoneal in all cases; 4 out of 7 patients (57%) also had additional adrenal, 3 out of 7 (42%) paraganglion and 1 out of 7 (14%) thoracic primaries.
  • After induction chemotherapy and delayed surgery, 6 out of 7 (86%) patients showed a complete remission (CR) and the mean CR lasted for about 27.7 months (range 3.1-55.4 months).
  • At the last time of follow-up 5 out of 7 (71%) patients were alive, 2 had died due to recurrent disease.
  • Mean time to recurrent disease was 24 and 51 months, respectively.
  • Mean overall survival time since diagnosis was 38.3 months (11-64 months) and mean event-free survival was 34.5 months (11-60.3 months).
  • The final outcome, overall survival and event-free survival time was influenced by metastatic or local relapse.
  • Tumor resection is beneficial but the value of surgery can only be judged when we are able to control metastatic disease in stage IV neuroblastoma.
  • The final outcome may rely on the extent of complete surgical resection, but is also related to treatment of metastases.
  • [MeSH-major] Neuroblastoma / surgery. Retroperitoneal Neoplasms / surgery
  • [MeSH-minor] Child, Preschool. Female. Humans. Infant. Male. Neoplasm Staging

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1256-64 [9552023.001]
  • [Cites] Klin Padiatr. 1997 Jul-Aug;209(4):196-200 [9293450.001]
  • [Cites] Pediatr Surg Int. 2002 Sep;18(5-6):289-94 [12415341.001]
  • [Cites] Eur J Pediatr Surg. 2002 Dec;12 (6):402-9 [12548494.001]
  • [Cites] J Clin Oncol. 1993 Aug;11(8):1466-77 [8336186.001]
  • [Cites] J Pediatr Surg. 1998 Oct;33(10):1526-30 [9802806.001]
  • [Cites] J Pediatr Surg. 1998 Feb;33(2):161-4 [9498379.001]
  • [Cites] J Pediatr Hematol Oncol. 1999 May-Jun;21(3):190-7 [10363851.001]
  • [Cites] Eur J Cancer. 1995 Jun;31A(6):993-9 [7646935.001]
  • [Cites] J Pediatr Surg. 2002 Nov;37(11):1574-8 [12407542.001]
  • [Cites] Eur J Surg Oncol. 1993 Feb;19(1):33-6 [8436238.001]
  • [Cites] J Pediatr Surg. 1983 Apr;18(2):147-51 [6854493.001]
  • [Cites] Eur J Cancer. 1997 Aug;33(9):1430-7; discussion 1437-8 [9337686.001]
  • [Cites] J Pediatr Surg. 1997 Nov;32(11):1616-9 [9396539.001]
  • [Cites] J Pediatr Surg. 1994 Aug;29(8):1162-5; discussion 1165-6 [7965527.001]
  • [Cites] Eur J Cancer. 1997 Oct;33(12):2092-7 [9516860.001]
  • [Cites] J Pediatr Surg. 1994 Feb;29(2):128-33 [8176583.001]
  • [Cites] N Engl J Med. 1999 Oct 14;341(16):1165-73 [10519894.001]
  • [Cites] Z Kinderchir. 1989 Feb;44(1):21-4 [2718635.001]
  • [Cites] J Natl Cancer Inst. 1997 Mar 5;89(5):373-80 [9060959.001]
  • [Cites] J Pediatr Surg. 1991 Sep;26(9):1119-23; discussion 1123-4 [1941492.001]
  • [Cites] Ann Oncol. 2002 Jun;13(6):956-64 [12123342.001]
  • [Cites] J Pediatr Surg. 1991 Sep;26(9):1113-7; discussion 1117-8 [1941491.001]
  • (PMID = 15372191.001).
  • [ISSN] 0724-4983
  • [Journal-full-title] World journal of urology
  • [ISO-abbreviation] World J Urol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


21. Paulino AC, Mayr NA, Simon JH, Buatti JM: Locoregional control in infants with neuroblastoma: role of radiation therapy and late toxicity. Int J Radiat Oncol Biol Phys; 2002 Mar 15;52(4):1025-31
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Locoregional control in infants with neuroblastoma: role of radiation therapy and late toxicity.
  • PURPOSE: To review patterns of failure in infants with neuroblastoma and determine late toxicity and efficacy of radiotherapy (RT) on locoregional control.
  • MATERIALS AND METHODS: From 1955 to 1998, 53 children (35 males and 18 females) <1 year old with neuroblastoma were seen at our institution.
  • All infants were retrospectively staged according to the International Neuroblastoma Staging System (INSS); 8 had Stage 1, 7 Stage 2A, 6 Stage 2B, 15 Stage 3, 6 Stage 4, and 11 Stage 4S.
  • Postoperative doses ranged from 15 to 25 Gy whereas preoperative doses ranged from 12 to 31 Gy using a median fraction size of 1.5 Gy.
  • Chemotherapy was employed in 22 of 53 patients (42%) with the most common agents being cyclophosphamide in 22 and doxorubicin in 11.
  • Five of 6 infants <6 months of age and 1 of 7 >/=6 months developed musculoskeletal toxicity.
  • Musculoskeletal effects were seen in 6 RT patients and included bony hypoplasia in 6, scoliosis in 5, soft tissue hypoplasia in 3, slipped capital femoral epiphysis in 2, kyphosis in 1, and osteochondroma in 1.
  • Three required orthopedic intervention, all receiving >/=20 Gy.
  • One child developed bowel obstruction at 21 months and another developed a leiomyosarcoma in the treatment field 34 years after RT.
  • Further studies are needed to determine if cardiovascular anomalies are more frequently seen in children with neuroblastoma.
  • [MeSH-major] Neuroblastoma / radiotherapy
  • [MeSH-minor] Abdominal Neoplasms / mortality. Abdominal Neoplasms / pathology. Abdominal Neoplasms / radiotherapy. Combined Modality Therapy. Disease Progression. Female. Humans. Infant. Infant, Newborn. Lymphatic Metastasis. Male. Musculoskeletal Diseases / etiology. Neoplasm Staging. Pelvic Neoplasms / mortality. Pelvic Neoplasms / pathology. Pelvic Neoplasms / radiotherapy. Radiation Injuries / complications. Survival Rate. Thoracic Neoplasms / mortality. Thoracic Neoplasms / pathology. Thoracic Neoplasms / radiotherapy. Treatment Failure

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Int J Radiat Oncol Biol Phys. 2002 Dec 1;54(5):1575; author reply 1575 [12459387.001]
  • (PMID = 11958898.001).
  • [ISSN] 0360-3016
  • [Journal-full-title] International journal of radiation oncology, biology, physics
  • [ISO-abbreviation] Int. J. Radiat. Oncol. Biol. Phys.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


22. Kushner BH, LaQuaglia MP, Kramer K, Cheung NK: Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk. J Pediatr Hematol Oncol; 2004 Jan;26(1):35-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radically different treatment recommendations for newly diagnosed neuroblastoma: pitfalls in assessment of risk.
  • Neuroblastoma risk stratification is based on stage, age, and biology and prescribes surgery for low-risk disease, moderate-dose chemotherapy for intermediate-risk disease, and maximal therapy (including myeloablative treatment with stem cell transplantation) for high-risk disease.
  • Stage was defined by the International Neuroblastoma Staging System.
  • The first recommendations were for maximal therapy, but second opinions were radically different (ie, surgery alone).
  • Ages at diagnosis were 15 to 25 months.
  • All four patients did well without cytotoxic therapy (follow-up: 2 years 10 months plus to 4 years 8 months plus).
  • Patient 1 had abdominal and upper thoracic/supraclavicular masses (stage 4); the former was resected and the latter spontaneously regressed.
  • Biopsies of the latter showed no neuroblastoma and the primary tumor (with regional lymph nodes) was resected, changing stage from 4 to 2B.
  • Patient 4 had a pelvic mass, with unfavorable histopathology, and bilateral inguinal lymph node involvement (stage 3); all soft tissue disease was resected.
  • The absence of cortical bone and extensive bone marrow metastatic involvement in a young neuroblastoma patient should cause a shift in attention to biologic prognostic markers.
  • Some patients classified as having high-risk neuroblastoma might actually do well with no cytotoxic therapy.
  • [MeSH-major] Health Planning Guidelines. Neuroblastoma / diagnosis. Neuroblastoma / surgery
  • [MeSH-minor] Biomarkers / analysis. Child, Preschool. Diagnostic Imaging. Female. Humans. Infant. Neoplasm Staging. Risk Assessment. Treatment Outcome

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14707711.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers
  •  go-up   go-down


23. Yamada K, Sugiura H, Suzuki Y, Takahashi M: [A case of retroperitoneal neuroblastoma in an adult with extensive bone marrow metastasis]. Gan To Kagaku Ryoho; 2004 Nov;31(12):2065-8
Hazardous Substances Data Bank. VINCRISTINE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [A case of retroperitoneal neuroblastoma in an adult with extensive bone marrow metastasis].
  • We present a case of retroperitoneal neuroblastoma in a 27-year-old male with extensive bone marrow metastasis at the first presentation.
  • After the simple excision of the tumor, adjuvant multi-drug chemotherapy, consisting of vincristine, actinomycin-D, ifosfamide, doxorubicin, carboplatin and etoposide, was carried out for 17 months, leading to complete remission.
  • Ten months after completion of the chemotherapy, the tumor recurred with bone marrow metastasis.
  • He further developed thoracic vertebral metastases resulting in paraplegia, and died of the disease 41 months after the presentation.
  • The clinical course of this case, with its emphases especially on the effect of the chemotherapy, is described in this report.
  • Since the clinical characteristics and treatment strategies for adult neuroblastoma have not yet been well established, they remain to be investigated in detail.
  • [MeSH-major] Bone Marrow Neoplasms / secondary. Neuroblastoma / secondary. Retroperitoneal Neoplasms / pathology
  • [MeSH-minor] Adult. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carboplatin / administration & dosage. Dactinomycin / administration & dosage. Doxorubicin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Humans. Ifosfamide / administration & dosage. Male. Paraplegia / etiology. Skull Neoplasms / secondary. Vincristine / administration & dosage

  • Genetic Alliance. consumer health - Neuroblastoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • Hazardous Substances Data Bank. ETOPOSIDE .
  • Hazardous Substances Data Bank. IFOSFAMIDE .
  • Hazardous Substances Data Bank. CARBOPLATIN .
  • Hazardous Substances Data Bank. DACTINOMYCIN .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15570942.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 1CC1JFE158 / Dactinomycin; 5J49Q6B70F / Vincristine; 6PLQ3CP4P3 / Etoposide; 80168379AG / Doxorubicin; BG3F62OND5 / Carboplatin; UM20QQM95Y / Ifosfamide
  •  go-up   go-down


24. Vassal G, Giammarile F, Brooks M, Geoerger B, Couanet D, Michon J, Stockdale E, Schell M, Geoffray A, Gentet JC, Pichon F, Rubie H, Cisar L, Assadourian S, Morland B: A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG). Eur J Cancer; 2008 Nov;44(16):2453-60
MedlinePlus Health Information. consumer health - Neuroblastoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of irinotecan in children with relapsed or refractory neuroblastoma: a European cooperation of the Société Française d'Oncologie Pédiatrique (SFOP) and the United Kingdom Children Cancer Study Group (UKCCSG).
  • PURPOSE: To evaluate the efficacy and safety of irinotecan in paediatric recurrent or refractory neuroblastoma.
  • PATIENTS AND METHODS: Thirty seven patients aged between 6 months and < or = 20 years, with relapsed or refractory neuroblastoma, received irinotecan at 600 mg/m(2) administered as a 60-min infusion, every 3 weeks.
  • Median times to progression and survival were 1.4 months (range, 1.2-1.5 months) and 8.8 months (range, 6.7-11.3 months), respectively.
  • CONCLUSION: Irinotecan administered intravenously as a single agent every 3 weeks induced no objective response in relapsed or refractory neuroblastoma.
  • [MeSH-major] Abdominal Neoplasms / drug therapy. Antineoplastic Agents, Phytogenic / administration & dosage. Camptothecin / analogs & derivatives. Neuroblastoma / drug therapy. Thoracic Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Drug Resistance, Neoplasm. Female. Gastrointestinal Diseases / chemically induced. Hematologic Diseases / chemically induced. Humans. Infant. Injections, Intravenous. Male. Neoplasm Recurrence, Local / prevention & control. Prospective Studies. Treatment Outcome. Young Adult

  • Genetic Alliance. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18812255.001).
  • [ISSN] 1879-0852
  • [Journal-full-title] European journal of cancer (Oxford, England : 1990)
  • [ISO-abbreviation] Eur. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Phytogenic; 7673326042 / irinotecan; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


25. Frappaz D, Michon J, Coze C, Berger C, Plouvier E, Lasset C, Bernard JL, Stephan JL, Bouffet E, Buclon M, Combaret V, Fourquet A, Philip T, Zucker JM: LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis. J Clin Oncol; 2000 Feb;18(3):468-76
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] LMCE3 treatment strategy: results in 99 consecutively diagnosed stage 4 neuroblastomas in children older than 1 year at diagnosis.
  • PURPOSE: To tailor postinduction therapy for stage 4 neuroblastoma in children who are older than 1 year at diagnosis according to status after induction.
  • After induction with the French Society of Pediatric Oncology NB87 regimen and surgery, patients who were in complete remission immediately proceeded to consolidation therapy with vincristine, melphalan, and fractionated total-body irradiation (VMT).
  • All other patients underwent a postinduction strategy before VMT, either an additional megatherapy regimen or further chemotherapy with etoposide/carboplatin.
  • RESULTS: The progression-free survival (PFS) is 29% at 7 years from diagnosis, which compares favorably with that of a similar cohort of 72 patients previously reported by our group (LMCE1; PFS of 20% at 5 years and 8% at 14 years, P =.004).
  • In the multivariate analysis, only age younger than 3 years at diagnosis (P =.0085) and achievement of complete or very good partial remission after NB87 and surgery (P =.00024) remained significant.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Neuroblastoma / drug therapy. Neuroblastoma / radiotherapy. Retroperitoneal Neoplasms / drug therapy. Retroperitoneal Neoplasms / radiotherapy
  • [MeSH-minor] Child. Child, Preschool. Combined Modality Therapy. Disease-Free Survival. Female. Follow-Up Studies. Humans. Infant. Male. Multivariate Analysis. Pelvic Neoplasms / diagnosis. Pelvic Neoplasms / drug therapy. Pelvic Neoplasms / radiotherapy. Pelvic Neoplasms / surgery. Remission Induction. Thoracic Neoplasms / diagnosis. Thoracic Neoplasms / drug therapy. Thoracic Neoplasms / radiotherapy. Thoracic Neoplasms / surgery. Whole-Body Irradiation

  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 10653862.001).
  • [ISSN] 0732-183X
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


26. Kang CH, Kim YT, Jeon SH, Sung SW, Kim JH: Surgical treatment of malignant mediastinal neurogenic tumors in children. Eur J Cardiothorac Surg; 2007 Apr;31(4):725-30
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical treatment of malignant mediastinal neurogenic tumors in children.
  • INTRODUCTION: The aim of this study was to identify the role of surgical resection in the treatment of malignant mediastinal neurogenic tumors in children.
  • MATERIALS AND METHODS: Thirty-eight consecutive children, who underwent surgical resection of a malignant mediastinal neurogenic tumor between 1986 and 2004, were included in this study.
  • The tumor cell types were neuroblastoma in 23 patients (60.5%), ganglioneuroblastoma in 14 (36.8%), and malignant neuroepithelioma in 1 (2.6%).
  • Surgery was performed for curative resection in localized tumors and salvage resection of residual mediastinal masses after chemotherapy in stage IV tumors.
  • Of the 16 patients (42.1%) who underwent salvage resection, 14 had neuroblastoma and 2 ganglioneuroblastoma.
  • CONCLUSIONS: Surgical resection of localized malignant mediastinal neurogenic tumor in children showed good long-term survival, and salvage operations after chemotherapy showed acceptable long-term survival.
  • [MeSH-minor] Adolescent. Child. Child, Preschool. Female. Ganglioneuroblastoma / mortality. Ganglioneuroblastoma / surgery. Humans. Infant. Infant, Newborn. Male. Neoplasm Invasiveness. Neoplasm Metastasis. Neoplasm Staging. Neuroblastoma / mortality. Neuroblastoma / surgery. Postoperative Complications. Preoperative Care / methods. Retrospective Studies. Risk Factors. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17306984.001).
  • [ISSN] 1010-7940
  • [Journal-full-title] European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery
  • [ISO-abbreviation] Eur J Cardiothorac Surg
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


27. van den Berg H, van Rijn RR, Merks JH: Management of tumors of the chest wall in childhood: a review. J Pediatr Hematol Oncol; 2008 Mar;30(3):214-21
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Chest wall tumors in childhood are major challenges with respect to diagnostic workup and treatment.
  • Incidence rate is less than 1 per 1,000,000 and various benign and malignant diseases are noted.
  • From the malignant diseases, Ewing tumors and rhabdomyosarcoma tumors are most often seen.
  • Depending on diagnosis, staging, and age, therapy has to be tailored for each patient, which should be discussed in a multidisciplinary team setting.
  • Radical resection is in most cases the major component of treatment.
  • Use of chemotherapy depends on the diagnosis.
  • In soft-tissue tumors, previously considered to be chemotherapy insensitive, favorable results are currently reported.
  • [MeSH-major] Lymphoma / therapy. Neuroblastoma / therapy. Rhabdomyosarcoma / therapy. Sarcoma, Ewing / therapy. Thoracic Neoplasms / therapy. Thoracic Wall / pathology
  • [MeSH-minor] Child. Combined Modality Therapy. Female. Humans. Male. Predictive Value of Tests

  • MedlinePlus Health Information. consumer health - Lymphoma.
  • MedlinePlus Health Information. consumer health - Neuroblastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18376284.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 63
  •  go-up   go-down


28. Martinsen A, Baccelli C, Navarro I, Abad A, Quetin-Leclercq J, Morel N: Vascular activity of a natural diterpene isolated from Croton zambesicus and of a structurally similar synthetic trachylobane. Vascul Pharmacol; 2010 Jan-Feb;52(1-2):63-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Furthermore, DT10 significantly inhibited calcium channel current recorded by the patch-clamp technique in human neuroblastoma cells SH-SY5Y.
  • In conclusion, these data suggest that vasorelaxant activity of diterpenes (DT) is associated with the blockade of L-type voltage-operated calcium channels.
  • Inhibition of NO-dependent relaxation by DT could be related to a decrease in NO availability.
  • [MeSH-major] Aorta, Thoracic / drug effects. Croton. Diterpenes / pharmacology. Plant Extracts / pharmacology. Vasodilation / drug effects
  • [MeSH-minor] Animals. Dose-Response Relationship, Drug. In Vitro Techniques. Male. Rats. Rats, Wistar. Structure-Activity Relationship

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] 2009 Elsevier Inc. All rights reserved.
  • (PMID = 19951744.001).
  • [ISSN] 1879-3649
  • [Journal-full-title] Vascular pharmacology
  • [ISO-abbreviation] Vascul. Pharmacol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Diterpenes; 0 / Plant Extracts
  •  go-up   go-down


29. Drut R, Drut RM, Pollono D, Tomarchio S, Ibáñez O, Urrutia A, Ripoll MC: Fine-needle aspiration biopsy in pediatric oncology patients: a review of experience with 829 patients (899 biopsies). J Pediatr Hematol Oncol; 2005 Jul;27(7):370-6
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • The procedure followed standard methods (22- to 24-gauge needle; mean of six alcohol-fixed and/or air-dried, H&E- or Giemsa-like-stained smears/procedure; leftover clots processed as a biopsy).
  • Smears diagnosed as positive for malignant cells were reported in 510 samples (56.7%) (463 patients); 1.89% of the smears were found inadequate for diagnosis.
  • NMYC status was determined on neuroblastoma samples by fluorescent in situ hybridization.
  • Overall sensitivity of the procedure was 98% (500/510 FNAB); specificity was 92.6% (463/500 FNAB); positive predictive value was 1 and negative predictive value was 0.99.
  • The procedure was found to be extremely helpful when deciding on preoperative chemotherapy.
  • [MeSH-minor] Abdominal Neoplasms / pathology. Adolescent. Adult. Child. Child, Preschool. Female. Head and Neck Neoplasms / pathology. Humans. Infant. Male. Reproducibility of Results. Retrospective Studies. Sensitivity and Specificity. Thoracic Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16012326.001).
  • [ISSN] 1077-4114
  • [Journal-full-title] Journal of pediatric hematology/oncology
  • [ISO-abbreviation] J. Pediatr. Hematol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


30. Soyer T, Karnak I, Ciftci AO, Senocak ME, Tanyel FC, Büyükpamukçu N: The results of surgical treatment of chest wall tumors in childhood. Pediatr Surg Int; 2006 Feb;22(2):135-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The results of surgical treatment of chest wall tumors in childhood.
  • Chest wall tumors (CWT) are rarely seen in childhood and surgery constitutes a complementary part of the therapy.
  • The diagnosis was malignant tumor in 12 (70%) and benign in 5 (30%).
  • They were Ewing's sarcoma (ES) (n = 4), primitive neuroectodermal tumor (PNET) (n = 3), Askin's tumor (n = 1), rhabdomyosarcoma (RMS) (n = 2), neuroblastoma (n = 2), osteochondroma (n = 1), aneurysmal bone cyst (n = 2) and hamartoma (n = 2).
  • Preoperative chemotherapy was given to most patients with malignant tumor.
  • All patients had only local tumor at the time of resection.
  • All tumor tissues with the affected rib/ribs were resected en bloc with the adjacent tissues.
  • All patients with malignant tumor received postoperative chemotherapy.
  • Five patients developed distant metastasis and two died.
  • Since most of the CWT are malignant and not initially suitable for surgical excision, the management includes tissue diagnosis either by tru-cut or open biopsy.
  • Determination of malignant condition should be followed by an intensive chemotherapy.
  • The patients should be closely followed up for late complications such as scoliosis, restrictive pulmonary disease and for the development of metastasis, which is a part of natural course of malignant CWT in children.
  • [MeSH-major] Thoracic Neoplasms / surgery. Thoracic Wall
  • [MeSH-minor] Adolescent. Chemotherapy, Adjuvant. Child. Child, Preschool. Female. Humans. Male. Neoadjuvant Therapy. Reconstructive Surgical Procedures. Retrospective Studies

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Pediatr Surg. 1994 Nov;3(4):267-76 [7850367.001]
  • [Cites] Spine (Phila Pa 1976). 1985 Sep;10 (7):618-22 [4071270.001]
  • [Cites] J Pediatr Surg. 1977 Dec;12(6):991-9 [201742.001]
  • [Cites] J Pediatr Surg. 1980 Dec;15(6):906-12 [7463293.001]
  • [Cites] Plast Reconstr Surg. 1996 Oct;98(5):804-10 [8823018.001]
  • [Cites] J Pediatr Surg. 1999 Dec;34(12):1773-8 [10626852.001]
  • [Cites] Ann Thorac Surg. 1988 Jul;46(1):40-4 [3382285.001]
  • [Cites] J Pediatr Surg. 1988 Jul;23(7):667-73 [3204468.001]
  • [Cites] J Thorac Cardiovasc Surg. 2000 Jun;119(6):1154-61 [10838532.001]
  • [Cites] J Thorac Cardiovasc Surg. 1999 Mar;117(3):588-91; discussion 591-2 [10047664.001]
  • [Cites] J Spinal Disord. 1994 Dec;7(6):522-7 [7873852.001]
  • [Cites] J Pediatr Surg. 1978 Jun;13(3):275-80 [209164.001]
  • [Cites] J Pediatr Surg. 1994 Sep;29(9):1189-91 [7807342.001]
  • (PMID = 16328338.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Germany
  •  go-up   go-down


31. Ishikawa N, Sato H, Tsunezuka Y, Hiranuma C, Ueno Y, Kurumaya H: Pulmonary blastoma in a child: report of a case. Surg Today; 2001;31(8):705-7
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Computed tomography and magnetic resonance imaging showed a marginally and heterogeneously enhanced tumor filling the left hemithorax.
  • Pathologic findings of the fine-needle aspiration were suggestive of neuroblastoma.
  • Subsequently, a left pneumonectomy with lymph node dissection was performed and histopathological examination confirmed that the tumor was a PB (type III).
  • After the definitive diagnosis was made the patient received combination chemotherapy, and no evidence of recurrence has been seen in the 5 months since surgery.

  • Genetic Alliance. consumer health - Blastoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11510607.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


32. Sacristán A, García de Miguel P, Antelo C, Ruza F, García García S, Pino García JM: [Respiratory function in pediatric survivors of malignant neoplasms]. An Esp Pediatr; 2000 Jun;52(6):516-22
MedlinePlus Health Information. consumer health - Cancer in Children.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Respiratory function in pediatric survivors of malignant neoplasms].
  • AIM: To evaluate post-treatment pulmonary function in patients with malignant extrapulmonary neoplasia and its relationship with age, type of neoplasty and treatment received.
  • METHODS: Cohort study of 95 pediatric patients after chemotherapy with or without surgery or extrapulmonary thoracic radiotherapy.
  • The patients were in remission without treatment and able to undergo pulmonary function testing.
  • RESULTS: Mean age at diagnosis was 5 +/- 3.3 years.
  • Treatment duration was 2.4 +/- 1.3 years and time without treatment 4.3 +/- 3. 3 years.
  • These alterations improved with time.
  • Thoracic surgery was the main cause of thoracic deformity and therefore of restrictive change.
  • The children under 8 years old and those who received longer treatments tended to show the worst TLCO values.
  • The patients with neuroblastoma showed greater restrictive change while the change in TLCO was more frequent in patients with Burkitt s lymphoma and in those treated with cyclophosphamide.
  • Restrictive change in pulmonary function was greater in patients who had undergone thoracic surgery.
  • Functional values were worse in patients with neuroblastoma.
  • Pulmonary function should be followed up in pediatric survivors of malignant neoplasia in order to prevent restrictive alterations.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11003959.001).
  • [ISSN] 0302-4342
  • [Journal-full-title] Anales españoles de pediatría
  • [ISO-abbreviation] An. Esp. Pediatr.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] SPAIN
  •  go-up   go-down


33. Browne GJ, Currow K, Rainbow J: Practical approach to the febrile child in the emergency department. Emerg Med (Fremantle); 2001 Dec;13(4):426-35
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [MeSH-major] Emergency Medicine / methods. Emergency Service, Hospital. Fever / therapy. Pediatrics / methods
  • [MeSH-minor] Anti-Bacterial Agents / therapeutic use. Bacterial Infections / complications. Bacterial Infections / diagnosis. Bacterial Infections / therapy. Body Temperature. Diagnosis, Differential. Drug Resistance, Bacterial. Female. Humans. Infant. Male. Neuroblastoma / complications. Neuroblastoma / radiography. New South Wales. Thermometers / standards. Thoracic Neoplasms / complications. Thoracic Neoplasms / radiography

  • MedlinePlus Health Information. consumer health - Children's Health.
  • MedlinePlus Health Information. consumer health - Fever.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11903427.001).
  • [ISSN] 1035-6851
  • [Journal-full-title] Emergency medicine (Fremantle, W.A.)
  • [ISO-abbreviation] Emerg Med (Fremantle)
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Anti-Bacterial Agents
  • [Number-of-references] 21
  •  go-up   go-down






Advertisement